Updated 2026-11-16. Refreshed weekly (see How this page stays current at the bottom).
This week (checked 2026-11-16; window 11–16 Nov)
- What changed: nothing new from the company at primary sources. The newsroom listing (colossal.com/news, read 16 Nov) has been re-dated: all eight newest items now show 12 or 13 Nov 2026, but every one is an older story re-posted. They include the moa egg (20 Oct), the TIME artificial egg (15 Oct), Paw Patrol (24 Aug) and the screwworm gene drive (15 Jun). Three of them cite their source outlet: GenoMorph (two items, both from TechCrunch, 14 Oct), "De-Extinction Science Could Also Advance Human Healthcare" (CNBC, Colleen McKown, 10 Oct) and "Confirms UAE Biovault Partnership and Opens Its Dallas Lab to Media for the First Time" (Forbes, David Bloom, 12 Mar 2026). The re-posted pages carry no date of their own. No round, spin-out, new BioVault partner, paper, prize or open call.
- New to this page, not new news: (1) Colossal's re-post of the 10 Oct CNBC story (CNBC itself returned 403 on earlier checks) quotes Lamm saying the work "could have implications for gene therapies, targeted delivery for humans and genetic diseases, as well as plastic in the oceans". That is company-reported, with no programme or paper named. (2) The Forbes URL reads "colossals-615m-project", and a 7 Nov Glitchwire piece says "upward of $615 million". That adds a fourth capital figure to $435M / $555M / $635M (⚠️ Forbes not opened; see Facts).
- Kehler suit, secondary follow-ups (Glitchwire, 7 Nov; Grit Daily, Jordan French, 11 Nov; both read 16 Nov): the suit seeks unspecified damages and no trial date is set. Grit Daily alone says "three contracts". Glitchwire says he joined Neion Bio "as Head of Avian Sciences shortly after leaving", names Alex Spiro (Quinn Emanuel) as Colossal's counsel, and says patent records list Kehler as an inventor on a Felix Pets patent (patent not checked). Both report that "Neither Neion Bio nor Kehler has publicly responded". ⚠️ The sources disagree on dates: Glitchwire says he resigned on 14 Apr 2026, Grit Daily calls the same date the day he joined Neion, and the Statesman (last week) has him leaving in 2025 and consulting into 2026. None of them cites the complaint for the date. The Justia docket (1:2026cv03112) returned 403 again, so the counsel and the dates stay unconfirmed. All claims are allegations, not findings.
- Surfaced, not new: a separate federal case, Li v. Colossal Biosciences Inc. (N.D. Tex., 3:2026cv02477), filed 27 Jul 2026, shows up in a Justia search listing as a civil-rights complaint. ⚠️ The docket was not opened, so no details are recorded.
- Investor-side, not a Colossal event: Bloomberg (11 Nov, headline only, 403) calls The 81 Collection a "Colossal Biosciences backer" in a story on its $82M Fund II. The fund size is confirmed by secondary outlets (techstartups, startupresearcher), and none of them mentions Colossal. ⚠️ The backer tie stands on Bloomberg's headline alone.
- Round: still no close. Nothing dated 11–16 Nov reports one, so TWG at ~$25–26B stays reported, not closed.
- Warhound: nothing new in the window.
- Moonshots: EP310 (11 Nov) and EP311 (13 Nov) transcripts swept for Colossal / Ben Lam(b|m) / mammoth / dodo / dire wolf / Warhound / NeoGenesis / de-extinction / Astromech / moa / clon / extinct. There is one passing hit, EP310
0:51:21: "why would they pull a colossal? They'll do the exact opposite. They'll keep it all inhouse." Here Colossal is shorthand for the spin-out model, in an exchange on whether Anthropic will spin out companies. The speaker is not identified, and the tie is not restated. EP311 has zero hits on Colossal; its "clone" and "extinction" matches are about software. As a control, "Anthropic" returns 36 and 22 hits. - Mammoth and womb claims: no new Colossal statement or paper.
- Open programmes: none new. The Species Reintroduction Fund page (rewild.org, read 16 Nov) still says "Applications are currently closed. Please check back soon" and posts no dates. The existing watch row stands, so the submissions register gets no new row.
- Open: the Kehler docket, the relief sought and the 14 Apr date; the Li case; TWG close and price; Colossal's stake in Warhound and the $1.2B valuation; the second "cloning company" and the Brady dog; a paper behind "300 plus" and behind GenoMorph; capital raised ($435M / $555M / $615M / $635M); what Lamm said at Disrupt; the moa egg price; the dire-wolf pack expansion.
Previous check (2026-11-10; window 4–10 Nov)
- What changed: one item, a lawsuit Colossal filed. Newsroom: nothing dated 4–10 Nov (newest still 20 Oct, the moa egg; listing read 10 Nov). No round, spin-out, BioVault partner, paper, prize or open call.
- Trade-secrets suit (filed Fri 6 Nov, Austin): Colossal sued its former Vice President of Animal Sciences, James Kehler. It alleges he took the secrets of its gene-editing process and disclosed them to other companies after leaving (Austin American-Statesman, Paul Flahive, 6 Nov; read via the Yahoo syndication, because the Statesman page returned a bot challenge). The suit's own words, as quoted: "Forensic analysis of Kehler's Colossal laptop shows that prior to leaving he exfiltrated files containing Colossal confidential and trade secret information to a personal cloud account and multiple personal devices." The claims are the Texas Uniform Trade Secrets Act, the Defend Trade Secrets Act of 2016 and breach of contract. Per the article, he left in 2025 and consulted "into this year", after a three-year tenure. The article names two companies, Neion Bio (New York; bioengineers medicines into eggs) and Felix Pets (hypoallergenic cats), and states "Neither company is being sued." These are allegations, not findings. No response from the defendant is reported, and the relief sought is not stated. ⚠️ The docket (Justia, Colossal Biosciences Inc. v. Kehler, 1:2026cv03112, W.D. Tex. per the URL) returned 403 and was not read. Counsel (Alex Spiro, Quinn Emanuel) appears in one search summary only and is not confirmed.
- Round: still no close. Searches find nothing dated 4–10 Nov, so TWG at ~$25–26B stays reported, not closed. Aggregators repeat the Sep 2025 $120M extension and the Feb 2026 UAE $60M (Sacra, Multiples), but no primary source has appeared; neither enters the Facts table.
- Warhound: nothing new in the window. Every item found dates to the 22–23 Oct launch, so Colossal's stake and the $1.2B figure stay open.
- Moonshots: EP308 (4 Nov;
transcript.txtplus.vttcaptions) and EP309 (7 Nov;transcript.txt, Whisper.srtand ANATOMY) swept for Colossal / Ben Lam(b|m) / mammoth / dodo / dire wolf / Warhound / NeoGenesis / de-extinction / Astromech / moa / clon / extinct: zero hits in both. As a control, "Anthropic" returns hits in both files. The tie is not restated. - Mammoth and womb claims: no new Colossal statement or paper found; the "early 2030s" line and the 24-month claim stand as recorded.
- Open programmes: none new. The Species Reintroduction Fund page (rewild.org, read 10 Nov) now reads "Applications are currently closed. Please check back soon". It posts no dates at all, and still no 2027 window. The existing watch row stands, so the submissions register gets no new row.
- Open: the suit's docket, relief sought and any response; TWG close and price; Colossal's stake in Warhound and the $1.2B valuation; the second "cloning company" and the Brady dog; a paper behind "300 plus" and behind GenoMorph; $635M vs $555M vs $435M; what Lamm said at Disrupt; the moa egg price; the dire-wolf pack expansion.
Previous check (2026-11-04; window 29 Oct–4 Nov)
- What changed: nothing at primary sources. Colossal's newsroom has no item dated 29 Oct–4 Nov (newest still 20 Oct, the moa egg; listing read 4 Nov). No round close reported in the window, so TWG at ~$25–26B stays reported, not closed. The only Warhound item found in the window is an aggregator recap of the 22 Oct Fortune story (Hot Air, 1 Nov; nothing new in it), so the size of Colossal's economic interest and the $1.2B valuation stay open.
- Moonshots: EP307 (31 Oct; the only new episode, per the 4 Nov watch run) swept for Colossal / Ben Lam(b|m) / mammoth / dodo / dire wolf / Warhound / NeoGenesis / de-extinction / moa: two passing hits, no segment. (1) "Palmer and folks like Ben Lamb are very much sort of the analoges to Elon. There are very few entrepreneurs that make these huge bets" (
1:59:46, in the Palmer Luckey laptop discussion; Whisper spelling, speaker inferred). (2) "if they have artificial wombs at Colossal, they can, you know, sort of like put thousands into development at once" (2:11:57, a quip in a mechanical-vs-biological military-dogs exchange — Warhound-adjacent but Warhound not named; speaker not identified). The booking/investor tie is not restated in either. - Surfaced, not new: Colossal CSO Beth Shapiro on Huberman Lab, "Bringing Extinct Species Back to Life" — episode dated 5 Oct 2026 per third-party listings (hubermanlab.com not opened); outside the window and not previously on this page. ⚠️ Not read; noted for the record only.
- Open programmes: none new. The newsroom listing shows no prize, grant or open call in the window; the Species Reintroduction Fund watch row stands (no 2027 window posted as of 23 Oct), so the submissions register gets no new row.
- Open: unchanged — TWG close and price; Colossal's stake in Warhound and the $1.2B valuation; the second "cloning company" and the Brady dog; a paper behind "300 plus" and behind GenoMorph; $635M vs $555M vs $435M; what Lamm said at Disrupt; the moa egg price; the dire-wolf pack expansion.
Previous check (2026-10-29; window 23–29 Oct)
- What changed: Colossal's newsroom has no item dated 23–29 Oct (newest still 20 Oct, the moa egg; read 29 Oct). The week's Colossal news is Warhound, announced the evening of 22 Oct and not on last week's page.
- Warhound, at source (Fortune, Nick Lichtenberg, 22 Oct 7:43 PM ET, read 29 Oct): a Texas company out of stealth with a $200M seed; backers named include In-Q-Tel, Sequoia, ARK, Franklin Templeton, 8VC, Bob Nelsen, Breyer, Lux and "Neogenesis". CEO David Spirk (former Pentagon chief data officer). Fortune's own words: "Colossal licenses technology to Warhound and has an economic interest in it"; Lamm sits on the board. Lamm: "Palmer and I don't describe ourselves as co-founders", and Luckey "doesn't even own equity in the business"; Anduril supplies the gear. First dogs "in about two years"; the first group is "already… biobanked and… being edited now" (Lamm); "no signed customers yet." Fortune says the idea was born at Peter Diamandis' Moonshots Summit. ⚠️ No valuation in Fortune or Mother Jones (23 Oct, headline updated "to better reflect Palmer Luckey's role"); the $1.2B figure is attributed to Business Insider by aggregators and was not read. The dog-programme figures are the company's: Fortune has "more than 2,200 dog teams" and "more than 80%" bought from Europe; Mother Jones has "about 1,600 dogs" and "80 percent". Fast Company returned 403.
- Moonshots: EP306 (28 Oct) carries the Warhound segment (see the EP306 note below). It opens with the host's disclosure "one that I'm personally invested in through Neoenesis" (
1:33:27, Whisper spelling). New on tape: "Colossal bought the top two cloning companies. They famously cloned Tom Brady's dog" (1:37:17, panelist; speaker not identified). Only one purchase is confirmed: ViaGen Pets & Equine, announced Nov 2025 as Colossal's first acquisition (USA Today, via secondary reports). ⚠️ A second cloning company and the Brady dog were not checked. EP305 (carried over from last week) has one passing hit, "Ben Lamb level" (0:46:32), used as a benchmark for podcast guests; there is no Colossal segment. - Round: still no close. Searches find no report dated 23–29 Oct, so TWG at ~$25–26B stays reported, not closed. ⚠️ Aggregators (startupintros, no primary source) list a $60M Series C tranche, Feb 2026, UAE-led. That might bear on the $555M vs $635M gap, but it is unconfirmed and is not in the Facts table.
- Bluebuck: a search surfaced it, but it is not new. The PR Newswire release is dated 30 Apr 2026 (sixth species; "40-fold genome").
- Open programmes: none new. The Species Reintroduction Fund still has no 2027 window, so the existing watch row stands and the submissions register gets no new row.
- Open: TWG close and price; Colossal's stake in Warhound and the $1.2B valuation; the second "cloning company"; a paper behind "300 plus" and behind GenoMorph; $635M vs $555M vs $435M; what Lamm said at Disrupt; the moa egg price; the dire-wolf pack expansion.
Previous check (2026-10-23; window 17–23 Oct)
- What changed: two newsroom items, both animal and heritage stories; no round, spin-out, BioVault partner, paper or open call.
- Moa egg handed back (Mon 19 Oct): Colossal bought a giant moa egg at a public auction run by Artemis Gallery (Colorado) in June 2026, after about six decades in a private American collection (found 1966), and presented it to Ngāi Tahu leader Professor Te Maire Tau at the SAPE 2026 meeting in Christchurch (colossal.com, read 23 Oct; Gizmodo, Matthew Phelan, 19 Oct). Ngāi Tahu researchers direct the reattachment of the remaining fragments; Peter Jackson, who works with the Ngāi Tahu Research Centre and Canterbury Museum on the moa programme, says it "will very likely become only the ninth known nearly intact moa egg." Newsroom date 20 Oct; Bloomberg 19 Oct (403, not read). ⚠️ The price, "about $14,000", appears in one aggregator only (Briefs); Colossal and Gizmodo state none. ⚠️ One outlet places the handover at a December ceremony; Gizmodo says it happened on 19 Oct. No moa timeline in either source.
- Dire wolves at two (newsroom 19 Oct): health checks done for all three; Romulus 134 lb, Remus two pounds lighter, Khaleesi 102 lb (born Jan 2025); 2,000-acre preserve; Colossal is "planning to add more dire wolves to the pack", with no number or date (colossal.com, read 23 Oct; company-reported). This archive's wording stays "grey wolves edited toward dire-wolf traits" (see Unverified).
- Round: still no close. Newsroom has no funding item, and search finds nothing dated 17–23 Oct; TWG at ~$25–26B stays reported, not closed. The $435M / $555M / $635M capital question is unchanged.
- Disrupt talk: still no report of what Lamm said on 13 Oct. Astromech: no news found.
- Moonshots: EP303 (17 Oct) and EP304 (21 Oct) transcripts swept for Colossal / Ben Lam(b|m) / mammoth / dodo / moa / dire wolf / NeoGenesis / de-extinction: zero hits. The 23 Oct episode (EP305) is not on disk and was not checked; it goes into next week's run.
- Open programmes: the Species Reintroduction Fund page (rewild.org, read 23 Oct) still posts only the closed 1–27 Jan 2026 window, with no 2027 date. The existing watch row stands; nothing new to add to the submissions register.
- Open: TWG close and price; a paper behind "300 plus" and behind GenoMorph; $635M vs $555M vs $435M; what Lamm said at Disrupt; the moa egg price; the size and date of the dire-wolf pack expansion.
Previous check (2026-10-17)
- ★ The host's tie is now in his own writing (resolves the open question held since 4 Oct): on 14 Oct 2026 Peter Diamandis launched NeoGenesis Capital with Yianni Psaltis. His X post opens "Five years ago, I became an early investor in @Colossal Biosciences" (x.com returned 402; text from the search excerpt), his Metatrends newsletter of 15 Oct says "I was among the first investors in Colossal Biosciences" (read on the peter-diamandis refresh), and the firm's site (neogenesiscapital.com, read 17 Oct) calls him a seed investor in Colossal. The firm "invests in Colossal Biosciences and in companies built on Colossal's platform" (Fenwick, 14 Oct, "the closing of its first fund", no size); its portfolio page names Colossal, Breaking, Astromech and one stealth company. Its own disclosure text: fund principals hold personal interests in portfolio companies including Colossal; Lamm and Church hold no economic interest in NeoGenesis and take no part in its decisions; "Colossal and its affiliates have not endorsed or sponsored the fund." Form D for NeoGenesis Capital Fund I, LP was filed 1 Jul 2026, $33,080,000 sold (EDGAR, per the peter-diamandis page). So EP288's "one of my portfolio companies" is a self-reported seed stake, now written down; the theorg "Executive Advisor" listing stays unconfirmed. Colossal's own pages do not mention NeoGenesis.
- GenoMorph (announced Wed 14 Oct): an AI platform that picks edit targets where ancient DNA is thin; it "does not edit genes itself". Numbers as reported: ~2,300 DNA targets for dodo beak and facial structure (TechCrunch, Dominic-Madori Davis, 14 Oct; Colossal newsroom item dated 15 Oct, a re-post of an Inc. feature with no quotes), "about 2,350 genetic switches" (TIME, Jeffrey Kluger, 14 Oct); one high-quality dodo genome against 104 mammoth genomes (newsroom; TechCrunch says "about 100"); genomes and skull measurements from >70 bird species; Nicobar pigeon colony of 36 (TechCrunch). Dodo timeline per TIME: "early 2030s", Colossal scientists "five or so years". ⚠️ No paper or preprint named anywhere; company-reported.
- TIME Best Inventions 2026: the artificial egg is on the list (time.com, Sal Vaglica, 15 Oct, read): 26 live chickens; candidate species kākāpō, western ground parrot, Bermuda petrel; no moa or dodo date in the entry; main-list or special-mention placement not stated on the page. Colossal newsroom item 15 Oct.
- Ben Lamm at TechCrunch Disrupt (13–15 Oct, San Francisco): confirmed on TechCrunch's own speakers page ("CEO and Founder Colossal Biosciences"), which resolves last week's unconfirmed item; the session title "Can We Engineer Nature's Comeback?" (13 Oct, Real World AI Stage) is from one Spanish-language outlet only; no report of what he said found.
- Round: still no close. Nothing dated October reports a close; TWG at ~$25–26B stays reported, not closed. ⚠️ New discrepancy on capital raised: NeoGenesis's site states Colossal has "$635M+ capital raised", a $10.3B valuation, 260 employees, 57 PhDs and "3 announced spinouts" (Form Bio 2022 named as the first). Colossal's own Jan 2025 release said $435M total; a $120M Series C extension in Sep 2025 taking the total to "just over $555M" is reported by GenomeWeb (secondary, not opened; not in last week's table). The gap to $635M is unexplained; no Colossal page states a total.
- Moonshots: the 1 Oct (EP298), 5 Oct, 7 Oct and 15 Oct transcripts swept for Colossal / Ben Lamm / mammoth / dodo: one hit, 15 Oct episode
1:35:11"That's where Colossal comes in, right? So in the same… yes, ex utero gestation. Ex utero so we can have bigger brains." (Whisper, speakers inferred; a brain-size aside, not a segment). The booking tie is not restated, and NeoGenesis is not said on tape in these four. Lamm's CNBC pieces (2 Oct video, 10 Oct article) still not read (403). - Species Reintroduction Fund, now read at source (Re:wild page + the request-for-partnership PDF): up to $250,000/yr in grants, up to $50,000 per project per year, 12 months at a time; nonprofit, government and academic organisations only, no geographic limit; one-page expression of interest by email; the 2026 window was 1–27 Jan 2026 (closed); no 2027 date posted. Logged as a watch row in the submissions register (fit none).
- Open: TWG close and price; a paper behind "300 plus" and behind GenoMorph; $635M vs $555M vs $435M; what Lamm said at Disrupt; whether Colossal itself has restated the 2028 mammoth target; the theorg advisor listing.
Previous check (2026-10-11)
- Mammoth date moved (resolves last week's ⚠️): in a TIME piece dated 24 Aug 2026 (time.com, read 11 Oct) Ben Lamm says "We are thinking it will be in the early 2030s… We don't have a hard date. Not 2036, but not 2030 either." TIME gives the original targets as pregnancy 2027, birth 2028, and the edit estimate as "about 150—and rising" against an initial "about 60". The slip was picked up by secondary outlets on 27–28 Sep (Dexerto, La Voce di New York). So the 2028 target on this page is superseded; Coyne's "2030 or so" was imprecise. Colossal's own mammoth page still lists 65 genes (per Dexerto, not re-opened). Not a change inside the last 7 days, but new to this page.
- Round: still no close announced. Newsroom (colossal.com/news, read 11 Oct) has no funding item; newest item still 29 Sep 2026 (Gizmodo Science Fair). Search surfaces only the Jan 2025 Series C and the earlier "talks" reports (≥$20B Axios 20 Jul; up to $30B per Dealroom, secondary). TWG ~$25–26B stays reported, not closed.
- Newsroom items not previously logged: 10 Aug Colossal Foundation names seven species for the second cohort of its Species Reintroduction Fund (no amounts stated; cohort announcement, no open call seen); 30 Jun USFWS partnership ("more than 2,300 endangered species", per headline) · 15 Jun screwworm gene-drive proposal (relevant to the EP299 note below) · 19 May artificial-egg (26 chickens) and dunnart artificial-womb stage reports.
- Ben Lamm is listed for TechCrunch Disrupt 2026 (one Spanish-language report; not confirmed at TechCrunch).
- Open: TWG close and price; paper behind "300 plus"; Peter's tie; whether Colossal itself has restated 2028 (TIME quote is the CEO, secondary reports say "abandoned"). EP298/EP299 not swept. No open programme, prize, grant or call for outside entrants found, so no pipeline or operator-guide row.
Previous check (2026-10-05)
- Round: no close announced. Colossal's newsroom lists nothing on funding; search finds only the January 2025 $200M Series C at $10.2B. The ≥$20B talks (Axios, 20 Jul) and TWG at ~$25–26B (Axios Pro, 30 Sep) stay reported, not closed. Axios pages not re-opened this week.
- Newsroom (colossal.com/news, read 5 Oct): newest item 29 Sep 2026, a 2026 Gizmodo Science Fair prize for the genomic pipeline behind the dire-wolf and red-wolf work (company-posted; the award itself not checked at Gizmodo). Before it: 8 Sep Tasmanian tiger skull study; 24 Aug Paw Patrol partnership. No new spin-out, BioVault or round item.
- Tape-adjacent: Ben Lamm appeared at the CNBC AI Forum, video dated 2 Oct 2026 (page returned 403; content not read).
- Mammoth date: a critic's blog (Coyne, 5 Oct) says the firm has "pushed back the mammoth date to 2030 or so", with no source cited. ⚠️ Unverified; the stated target on this page stays 2028 until a Colossal statement says otherwise.
- Open: TWG close and price; paper behind "300 plus"; Peter's tie. EP298/EP299 not swept for Colossal. No open programme, prize, grant or call for outside entrants found (careers page is jobs only), so no pipeline or operator-guide row.
What it is (one line): the Dallas de-extinction and genome-engineering company led by Ben Lamm and
George Church; on the Moonshots with Peter Diamandis tape it is the host's own booked portfolio company (Moonshots #288
2:24:19) and the subject of a 43-minute guest segment (Moonshots #297).
Why it is in this archive
Gate: cited in 2 episodes (EP288 as "Ben Lamb's company", captioned; EP297 as the subject). Promoted 2026-10-04 off the EP297 decomposition. It earns the page for a second reason: it is the cleanest test case for the disclosure ledger, a tie the host booked on air and then did not restate for 43 minutes (Moonshots: the disclosures ledger).
Facts
| Founded / HQ | Dallas, Texas · co-founders Ben Lamm and George Church (per the company's own materials and press) |
| Last closed round | $200M Series C at a $10.2B valuation, January 2025; $435M total raised (TechCrunch) |
| Round in progress | reported in talks at ≥$20B (Axios, 2026-07-20); TWG Global (Mark Walter) expected to lead at ~$25–26B (Axios Pro, 2026-09-30; secondary, paywalled) · not closed |
| Spin-outs | Astromech (AI for evolutionary biology): $2B at spin-out, Mar 2026; $20M at $3.8B, Aug 2026, led by Bob Nelsen (Dealroom). NeoGenesis's site (17 Oct) counts "3 announced spinouts", naming Form Bio (2022, first) and holding Breaking (microplastics) in its portfolio; ⚠️ Breaking as a Colossal spin-out is not confirmed on a Colossal page. Warhound (working dogs, $200M seed, out of stealth 22 Oct 2026): Colossal "licenses technology to Warhound and has an economic interest in it" (Fortune); the size of the interest is not stated |
| Acquisition | ViaGen Pets & Equine (cloning, Texas), Nov 2025, Colossal's first (USA Today, via secondary reports; not re-read at source) |
| Host's tie | Peter Diamandis: self-reported seed / "among the first" investor (his X post 14 Oct 2026, newsletter 15 Oct, neogenesiscapital.com); his firm NeoGenesis Capital (Form D 1 Jul 2026, $33.08M sold) invests in Colossal and its platform companies. Not restated on EP297. The theorg "Executive Advisor" listing stays unconfirmed |
| Capital raised (total) | $435M per Colossal, Jan 2025 (primary); "just over $555M" after a reported $120M Series C extension, Sep 2025 (GenomeWeb, secondary); "$635M+" on NeoGenesis's site (17 Oct); $615M in a Forbes URL (12 Mar 2026, not opened) and in Glitchwire (7 Nov, "upward of $615 million") ⚠️ unexplained |
| Headline results | woolly mouse (Mar 2025): eight edits in seven genes · "dire wolves" (Apr 2025): grey wolves with 20 edits (15 in 14 genes) |
| Stated target | was first woolly-mammoth calf by 2028; Lamm to TIME (24 Aug 2026): "early 2030s… not 2036, but not 2030 either", no hard date; edit estimate ~150 and rising (22-month elephant gestation) |
| Conservation | BioVault network: Dubai (announced Feb 2026), US Fish & Wildlife Service (announced 2026-06-25; all ESA-listed species) (StreetInsider release) |
What was said on tape (EP297, 2026-09-25 recording)
- Ex-utero birth of a mammal "within 24 months" (
0:22:34). Colossal's recent framing of the 2028 mammoth plan is reported as not depending on the artificial womb (Screen Rant, ⚠️ secondary). The two are different programmes. - Genome editing: "We are delivering 300 plus at 90 plus percent efficiency consistently… We're testing
1,000" (
0:20:48–0:21:04). ⚠️ No unit, no paper. Barred. - Herd target: "tens of thousands" of mammoths, "16 different lines" at once (
0:29:33–0:29:43). - Conservation spend: a foundation, "75 global partners", funding Elephant Havens in Botswana
(
0:29:21,0:30:19). - Promptable biology within a decade (
0:19:54): "the CAD software for biology" is Peter's phrase, the decade is the guest's. - Astromech as a traffic-control layer for frontier models (
0:35:23–0:36:06).
Position
Colossal is simultaneously a science programme, a conservation charity-adjacent foundation, a venture studio (spin-outs carry their own valuations) and a media property. The panel treats the first and last as one thing. For an operator, the useful structure is that the revenue-bearing parts are the spin-outs and the BioVault government work, not the animals.
Where it came up
- Moonshots #288
2:24:19— Peter: "we're going to have back on the pod Ben Lamb, uh, one of my portfolio companies" - Moonshots #297 — the full segment (decomposition: the research archive)
- 2026-10-15 episode
1:35:11— "That's where Colossal comes in, right?… ex utero gestation" (brain-size aside; Whisper, speaker inferred; tie not restated) - Moonshots #307
1:59:46,2:11:57— Ben Lamm as a Luckey/Elon-class "mega entrepreneur" analogue; "artificial wombs at Colossal" quip in a mechanical-vs-biological dogs exchange (passing hits; speakers inferred; tie not restated) - Moonshots #310
0:51:21: "why would they pull a colossal?" Colossal is used as shorthand for the spin-out model in an Anthropic exchange (passing hit; speaker not identified; tie not restated)
Open questions
- Did the TWG round close, at what price? Re-check Axios and Colossal's newsroom weekly.
- Is there a paper or preprint behind the "300 plus" multiplex-editing figure?
- Peter's tie: investor, by his own word (14–15 Oct 2026) — "among the first investors", seed, now through NeoGenesis Capital (see This week). Still open: the size of the stake, and the Executive Advisor listing on a secondary directory (theorg.com), which no Colossal or NeoGenesis page repeats. ⚠️ Self-reported; no Colossal filing names him.
- Capital raised: $435M (company, Jan 2025) vs "just over $555M" (GenomeWeb, Sep 2025 extension) vs $615M (Forbes URL, Mar 2026; Glitchwire, Nov 2026) vs "$635M+" (NeoGenesis site, Oct 2026). Which is right, and was there an unannounced raise?
- Is there a paper or preprint behind GenoMorph's ~2,300 dodo targets?
- Warhound: how large is Colossal's economic interest, and is the $1.2B valuation (attributed to Business Insider) real?
- Does the artificial-womb programme have a publication behind the 24-month claim?
- Colossal v. Kehler (filed 6 Nov 2026): what does the docket show (court, relief, any answer), and does it go to Travis County as the agreements require, per the article? Did he resign on 14 Apr 2026 (Glitchwire) or in 2025 (Statesman)?
- Li v. Colossal Biosciences Inc. (N.D. Tex., filed 27 Jul 2026): what is it? The docket has not been read.
⚠️ Unverified
Everything in What was said on tape is the CEO's statement about his own company, with no document named on air. The dire-wolf characterisation is contested by the IUCN SSC Canid Specialist Group ("The three animals produced by Colossal are not dire wolves", NPR); this archive uses "grey wolves edited toward dire-wolf traits".
How this page stays current
A weekly pull (Mondays). Each step names the source and what to diff:
- colossal.com/news: diff the newest items; log any round, spin-out, BioVault partner, prize or open call.
- News, last 7 days ("Colossal Biosciences" + raises / valuation / Astromech / mammoth in Axios, TechCrunch, Bloomberg, Reuters): a round enters the Facts table only when announced or reported closed.
- Mammoth and womb claims: compare the stated 2028 target and the 24-month ex-utero claim with any Colossal statement or paper.
- Moonshots: sweep new transcripts for Colossal / Ben Lamm and re-read the disclosure tie.
- Bump
updated:and the Updated line. Anything not re-read at its source stays marked ⚠️.
EP306 note (2026-10-29): Warhound, and the tie restated through the fund
- Warhound is a company conceived by Ben Lamm and Palmer Luckey (Lamm to Fortune, 22 Oct: "Palmer and I don't describe ourselves as co-founders"; Colossal licenses it technology and has an economic interest in it). It edits cell lines from the best Malinois and German shepherds and clones the result as working dogs. The host read it on Moonshots #306
1:33:26–1:35:47: "Colossal is building Captain America. And [Anduril] is building the Iron Man suit". It raised a $200M seed at $1.2B (~22 Oct; In-Q-Tel, Sequoia, 8VC, ARK, Franklin Templeton, Breyer, NeoGenesis; TechCrunch, secondary). First births are expected early 2027. ⚠️ Luckey is a partner but reportedly holds no equity, and Anduril none. "Fewer than half [of imported dogs] fit for service" and American Humane certification were not found. "More than 80% from Europe" is the company's figure. - Tie restated: "It's investing in Colossal and all the spinouts, including Warhound" (
1:35:24, via NeoGenesis Capital). This is the first on-tape restatement since EP288. See Moonshots: the disclosures ledger.
EP299 note (2026-10-08)
Peter tied the mosquito executive order to "the exact kind of gan drive work that Colossal… is doing" (0:39:44, Moonshots #299). Unverified; Colossal's public work is de-extinction. The booking tie (Ben Lamm) is not restated.